(1AR,3S,4S,9S,15bR)-3,4,12-trihydroxy-14-methoxy-9-methyl-3,4,8,9-tetrahydro-1aH-benzo[c]oxireno[2,3-e][1]oxacyclotetradecine-5,11(2H,15bH)-dione
- Catalog No. :
- ACFEUN129
- CAS No. :
- 76958-67-3
- Molecular Formula :
- C19H22O8
- Molecular Weight :
- 378.38
IUPAC Name:(1aR,3S,4S,9S,15bR,Z)-3,4,12-trihydroxy-14-methoxy-9-methyl-1a,3,4,8,9,15b-hexahydro-5H-benzo[c]oxireno[2,3-e][1]oxacyclotetradecine-5,11(2H)-dione
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg99%$575.00Login to see priceInquiryInquiry
Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.
0 Reviews:View Reviews
Product Information
| Product Name | (1AR,3S,4S,9S,15bR)-3,4,12-trihydroxy-14-methoxy-9-methyl-3,4,8,9-tetrahydro-1aH-benzo[c]oxireno[2,3-e][1]oxacyclotetradecine-5,11(2H,15bH)-dione |
|---|---|
| IUPAC Name | (1aR,3S,4S,9S,15bR,Z)-3,4,12-trihydroxy-14-methoxy-9-methyl-1a,3,4,8,9,15b-hexahydro-5H-benzo[c]oxireno[2,3-e][1]oxacyclotetradecine-5,11(2H)-dione |
| Molecular Formula | C19H22O8 |
| Molecular Weight | 378.38 |
| SMILES | O=C1[C@@H](O)[C@@H](O)C[C@]2([H])[C@@](O2)([H])C3=CC(OC)=CC(O)=C3C(O[C@@H](C)C/C=C\1)=O |
| InChI Key | SSNQAUBBJYCSMY-KNTMUCJRSA-N |
| Synonym | HYPOTHEMYCIN;(1aR,3S,4S,6Z,9S,15bR)-1a,2,4,5,11,8,9,15b-Octahydro-3,4,12-trihydroxy-9-methyl-14-methoxy-3H-oxireno[k][2]benzoxacyclotetradecin-5,11-dione;(1aR,3S,4S,6Z,9S,15bR)-1a,8,9,15b-Tetrahydro-3,4,12-trihydroxy-9-methyl-14-methoxy-3H-oxireno[k][2]benzoxacyclotetradecin-5,11(2H,4H)-dione;Hypothemicin;Nsc354462;3H-Oxireno[k][2]benzoxacyclotetradecin-5,11(2H,4H)-dione,1a,8,9,15b-tetrahydro-3,4,12-trihydroxy-14-methoxy-9-methyl-,(1aR,3S,4S,6Z,9S,15bR)-;(1aR,3S,4S,6Z,9S,15bR)-1a,8,9,15b-Tetrahydro-3,4,12-trihydroxy-14-methoxy-9-methyl-3H-oxireno[k][2]benzoxacyclotetradecin-5,11(2H,4H)-dione;f 152 D2 |
| CAS No. | 76958-67-3 |
| PubChem CID | 254761812 |
Safety Data
- Pictogram
- Signal Word
- Warning
- Hazard Statement(s)
- H302
- Precautionary Statement(s)
- P301+P312+P330

